These findings not only inform ongoing clinical development but also provide a roadmap for anticipating and circumventing resistance mechanisms, ultimately working toward improving outcomes for the substantial population of BRAF-mutant NSCLC patients who currently lack effective targeted therapies. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.